Supernus Pharmaceuticals (SUPN) Finished Goods (2013 - 2026)

Supernus Pharmaceuticals (SUPN) has 14 years of Finished Goods data on file, last reported at $19.5 million in Q1 2026.

• On a quarterly basis, Finished Goods fell 11.46% year-over-year to $19.5 million in Q1 2026; TTM through Mar 2026 was $19.5 million, a 11.46% decrease from a year earlier, with the FY2025 full-year figure at $21.1 million, up 28.44% from the prior year.
• Finished Goods for Q1 2026 stood at $19.5 million, down from $21.1 million in the prior quarter.
• Over the last five years, Finished Goods for SUPN reached as high as $46.7 million in Q3 2022 and fell as low as $16.4 million in Q4 2024.
• Historically, Finished Goods has averaged $29.1 million across 5 years, with a median of $29.9 million in 2023.
• Across the five-year window, Finished Goods soared 272.49% in 2022 and tumbled 45.05% in 2024, its largest moves.
• Year by year, Finished Goods stood at $35.0 million in 2022, then declined by 14.54% to $29.9 million in 2023, then tumbled by 45.05% to $16.4 million in 2024, then advanced by 28.44% to $21.1 million in 2025, then declined by 7.48% to $19.5 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $19.5 million in Q1 2026, $21.1 million in Q4 2025, and $16.7 million in Q3 2025.